Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €87.17 EUR
Change Today +1.53 / 1.79%
Volume 9.6K
ADOC On Other Exchanges
EN Paris
As of 3:58 AM 09/3/15 All times are local (Market data is delayed by at least 15 minutes).

adocia sas (ADOC) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/21/15 - €94.24
52 Week Low
09/8/14 - €15.85
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ADOCIA SAS (ADOC)

Related News

No related news articles were found.

adocia sas (ADOC) Related Businessweek News

No Related Businessweek News Found

adocia sas (ADOC) Details

Adocia, a biotechnology company, develops medicines from therapeutic proteins. The company focuses on insulin therapy and the treatment of diabetic foot ulcer based on its BioChaperone technological platform. Its product pipeline includes BioChaperone PDGF-BB, which is in Phase III clinical trials for the treatment of diabetic foot ulcer; BioChaperone insulin that is in Phase II clinical trials, as well as in pre clinical stage for the treatment of diabetes; and Driveln, which is preclinical stage for the treatment of oncology. The company, through its collaboration partnerships with pharmaceutical companies, also develops formulations for monoclonal antibodies. Adocia Société Anonyme was founded in 2005 and is based in Lyon, France.

93 Employees
Last Reported Date: 07/23/15
Founded in 2005

adocia sas (ADOC) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: €461.9K
Co-Founder, Vice-President, Director of Resea...
Total Annual Compensation: €278.4K
Compensation as of Fiscal Year 2014.

adocia sas (ADOC) Key Developments

Adocia and Eli Lilly Initiate New Phase 1b Study of Repeated Administration of Ultra-Rapid Biochaperone Lispro in Patients with Type 1 Diabetes

Adocia and Eli Lilly and Company announced the initiation of a Phase 1b clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation of insulin lispro licensed to Lilly. This formulation uses Adocia’s proprietary technology BioChaperone, which is designed to accelerate insulin absorption. This new study under the Adocia-Lilly partnership aims to compare the effect of BioChaperone Lispro, injected either at mealtime or 15 minutes after the meal, on post-meal glycemic control in type 1 diabetes patients to that of Humalog® (insulin lispro rDNA origin) over the same two-week period. Commercialized fast-acting insulin analogs are usually injected before the meal. An ultra-rapid insulin aims to allow injection at the time of the meal, or even after the start of a meal, with the goal of reducing the magnitude of glycemic excursions. In this crossover, randomized, double-blind study, 36 type 1 diabetes patients will receive multiple daily doses of BioChaperone Lispro and Humalog over two periods of 14 days each. The main objective is to compare post-meal glucose profiles after identical bolus injections of either BioChaperone Lispro or Humalog relative to a solid meal stimulus. Additionally the study will document the safety and efficacy of an ultra-rapid insulin absorption profile in an outpatient setting. This study will be sponsored by Adocia, and performed by Profil Neuss in Germany. Additional Phase 1b clinical studies will be conducted this year in order to understand performance for additional diabetic patient needs.

Adocia Reports Consolidated Earnings Results for the First Six Months Ended June 30, 2015

Adocia reported consolidated earnings results for the first six months ended June 30, 2015. For the period, the company reported operating revenue of EUR 16,674,000 against EUR 1,874,000 a year ago. Operating income was EUR 4,815,000 against operating loss of EUR 5,559,000 a year ago. Net income was EUR 6,719,000 against net loss of EUR 5,545,000 a year ago. Diluted net earnings per share were EUR 1.0 against diluted net loss per share of EUR 0.9 a year ago. Revenue was EUR 12,709,000 against EUR 186,000 a year ago. Revenues were resulted primarily from the collaborative and licensing agreement signed with Lilly end of 2014.

Adocia Société Anonyme, Board Meeting, Jul 20, 2015

Adocia Société Anonyme, Board Meeting, Jul 20, 2015. Agenda: To consider earnings results for the first six months ended June 30, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ADOC:FP €87.17 EUR +1.53

ADOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ADOC.
View Industry Companies

Industry Analysis


Industry Average

Valuation ADOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 28.8x
Price/Book 13.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 26.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ADOCIA SAS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at